Sugi Predict

Sugi Predict / Compounds / SCHEMBL913374

SCHEMBL913374

SCHEMBL913374

O=c1oc(-c2cccs2)nc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 1.00
▸ HPGD P15428 5/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ SMN1; SMN2 Q16637 3/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ F2 P00734 2/20 1.00
▸ KDM4E B2RXH2 9/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ CYP2C19 P33261 1/20 0.68
▸ HSD17B10 Q99714 3/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ ELANE P08246 3/20 0.61
▸ GAA P10253 2/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ MAPT P10636 1/20 0.58
▸ PKM P14618 1/20 0.56
▸ C1R P00736 4/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ PLG P00747 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7387892 0.82 ALDH1A1 (0.70) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL2544499 0.82 ALDH1A1 (0.69) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL914097 0.81 ALDH1A1 (0.81) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL913449 0.81 ALDH1A1 (1.00) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL13701234 0.81 ALDH1A1 (0.72) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL272287 0.81 ELANE (0.81) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL13701129 0.81 ALDH1A1 (0.68) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL915806 0.80 HSD17B10 (0.67) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL8059761 0.78 MAPK1 (0.72) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1
SCHEMBL8070379 0.78 KDM4E (0.75) ALDH1A1HPGDKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872052-B2 Use of heterocyclic compounds as SCCE inhibitors AREXIS AB (SE) 2011-01-18 — — US claimed
US-20060258651-A1 Use of heterocyclic compounds as scce inhibitors QUANTUM LTO HOLDINGS, LLC 2006-11-16 — — US claimed
EP-1631295-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER Arexis AB (SE) 2006-03-08 — — EP claimed
WO-2004108139-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER AREXIS AB (SE) 2004-12-16 — — WO claimed
WO-2003007955-A2 BIPHENYL APURINIC/APYRIMIDINIC SITE ENDONUCLEASE INHIBITORS TO TREAT CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-01-30 — — WO claimed
US-6180625-B1 MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS NOVO NORDISK A/S (DK) 2001-01-30 — — US claimed
CN-122010914-A Quinazoline-coumarin compound and preparation method and application thereof 郑州大学 2026-05-12 — — CN disclosed
CN-117935945-A Screening method of Cu-TEMPO catalytic system 内蒙古工业大学 2024-04-26 — — CN disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 — — US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 — — US disclosed
US-20210033886-A1 LENS FOR SPECTACLES AND SPECTACLES FUJIFILM CORPORATION (JP) 2021-02-04 — — US disclosed
US-8304538-B2 Method of producing benzoxazinone-based compound FUJIFILM CORPORATION (JP) 2012-11-06 — — US disclosed
EP-0067382-A2 N-cyclohexyl-chloroacetamides, their preparation and their use in combating undesired plant growth BASF Aktiengesellschaft (DE) 1982-12-22 — — EP disclosed
US-4363651-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1982-12-14 — — US disclosed
EP-0053678-A1 5-Amino-1-phenyl-4-cyano pyrazoles, herbicides containing them, process for their preparation and their use as herbicides BASF Aktiengesellschaft (DE) 1982-06-16 — — EP disclosed
EP-0053698-A1 5-Amino-1-phenylpyrazole-4-carboxylic acids, process for their preparation, herbicides containing them and their use as herbicides BASF Aktiengesellschaft (DE) 1982-06-16 — — EP disclosed
EP-0049398-A1 4H-3,1-Benzoxazin derivatives, process for their preparation and their use as herbicides BASF Aktiengesellschaft (DE) 1982-04-14 — — EP disclosed
US-3970652-A Selectively herbicidal 2-substituted-4H-3,1-benzoxazin-4-ones GULF RESEARCH & DEVELOPMENT COMPANY (US) 1976-07-20 — — US disclosed
US-3970652-A Selectively herbicidal 2-substituted-4H-3,1-benzoxazin-4-ones GULF RESEARCH & DEVELOPMENT COMPANY (US) 1976-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ALDH1A1 4701/4885HPGD 4052/4885KMT2A 2987/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4701/4885HPGD 4052/4885KMT2A 2987/4885
US-20060258651-A1 Use of heterocyclic compounds as scce inhibitors RCE1, CTSE, SPINT2 ALDH1A1 584/4885HPGD 73/4885KMT2A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.